Drug Profile
Prexasertib - Acrivon Therapeutics/SOM Biotech
Alternative Names: ACR 368; Captisol® enabled prexasertib; LY 2606368 MsOH H2O; LY-2606368; Prexasertib Mesylate Monohydrate - Acrivon Therapeutics/ SOM BiotechLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Array BioPharma; Eli Lilly and Company
- Developer Acrivon Therapeutics; Children's Oncology Group; Dana-Farber Cancer Institute; Eli Lilly and Company; Ewha Womans University; National Cancer Institute (USA); SOM Biotech
- Class Antineoplastics; Antivirals; Nitriles; Pyrazines; Pyrazoles; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bladder cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Phase I/II Urogenital cancer
- Preclinical COVID 2019 infections
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 25 Sep 2023 Phase-II clinical trials in Endometrial cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (Acrivon Therapeutics pipeline, September 2023)
- 09 May 2023 Prexasertib - Acrivon Therapeutics/SOM Biotech receives Fast Track designation for Endometrial cancer [IV] (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
- 09 May 2023 Prexasertib - Acrivon Therapeutics/SOM Biotech receives Fast Track designation for Ovarian cancer (Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA